Cargando…

Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women

OBJECTIVE: To describe the clinical presentation and laboratory diagnosis of pregnant women with respiratory syncytial virus (RSV) infection. METHODS: Pregnant women in their second and third trimester were enrolled during the course of routine prenatal care visits when they were asymptomatic within...

Descripción completa

Detalles Bibliográficos
Autores principales: Hause, Anne M., Avadhanula, Vasanthi, Maccato, Maurizio L., Pinell, Phillip M., Bond, Nanette, Santarcangelo, Patricia, Ferlic-Stark, Laura, Ye, Xunyan, Iwuchukwu, Obinna, Maurer, Lauren, Aideyan, Letisha, Dao, Kelly, McBride, Trevor, Piedra, Pedro A., Munoz, Flor M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126758/
https://www.ncbi.nlm.nih.gov/pubmed/31085002
http://dx.doi.org/10.1016/j.vaccine.2019.04.098
_version_ 1783516214768697344
author Hause, Anne M.
Avadhanula, Vasanthi
Maccato, Maurizio L.
Pinell, Phillip M.
Bond, Nanette
Santarcangelo, Patricia
Ferlic-Stark, Laura
Ye, Xunyan
Iwuchukwu, Obinna
Maurer, Lauren
Aideyan, Letisha
Dao, Kelly
McBride, Trevor
Piedra, Pedro A.
Munoz, Flor M.
author_facet Hause, Anne M.
Avadhanula, Vasanthi
Maccato, Maurizio L.
Pinell, Phillip M.
Bond, Nanette
Santarcangelo, Patricia
Ferlic-Stark, Laura
Ye, Xunyan
Iwuchukwu, Obinna
Maurer, Lauren
Aideyan, Letisha
Dao, Kelly
McBride, Trevor
Piedra, Pedro A.
Munoz, Flor M.
author_sort Hause, Anne M.
collection PubMed
description OBJECTIVE: To describe the clinical presentation and laboratory diagnosis of pregnant women with respiratory syncytial virus (RSV) infection. METHODS: Pregnant women in their second and third trimester were enrolled during the course of routine prenatal care visits when they were asymptomatic within the preceding two weeks (healthy controls) or when they reported symptoms of acute respiratory illness (ARI) of ≤7 days of duration (cases). Clinical outcomes were assessed at enrollment and two weeks after. Re-enrollment was allowed. Nasal-pharyngeal secretions were evaluated for respiratory pathogens by real-time reverse transcription polymerase chain reaction (PCR). Sera were tested for RSV-specific antibody responses by Western Blot, microneutralization assay, and palivizumab competitive antibody assay. RESULTS: During the 2015–2016 respiratory virus season, 7 of 65 (11%) pregnant women with ARI at their initial enrollment and 8 of 77 (10%) pregnant women with ARI during the study period (initial or re-enrollment) had PCR-confirmed RSV infection. Four (50%) PCR-confirmed RSV ARI cases reported symptoms of a lower respiratory tract illness (LRTI), one was hospitalized. Combining PCR and serology data, the RSV attack rate at initial enrollment was 12% (8 of 65), and 13% (10 of 77) based on ARI episodes. Among healthy controls, 28 of 88 (32%) had a Western Blot profile suggestive of a recent RSV infection either in the prior and/or current season. CONCLUSION: RSV had an attack rate of 10–13% among ambulatory pregnant women receiving routine prenatal care during the respiratory virus season. The serology results of healthy controls suggest a potentially higher attack rate. Future studies should be aware of the combined diagnostic strength of PCR and serology to identify RSV infection. As maternal RSV vaccine candidates are evaluated to protect young infants, additional priority should be placed on outcomes of pregnant women.
format Online
Article
Text
id pubmed-7126758
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71267582020-04-08 Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women Hause, Anne M. Avadhanula, Vasanthi Maccato, Maurizio L. Pinell, Phillip M. Bond, Nanette Santarcangelo, Patricia Ferlic-Stark, Laura Ye, Xunyan Iwuchukwu, Obinna Maurer, Lauren Aideyan, Letisha Dao, Kelly McBride, Trevor Piedra, Pedro A. Munoz, Flor M. Vaccine Article OBJECTIVE: To describe the clinical presentation and laboratory diagnosis of pregnant women with respiratory syncytial virus (RSV) infection. METHODS: Pregnant women in their second and third trimester were enrolled during the course of routine prenatal care visits when they were asymptomatic within the preceding two weeks (healthy controls) or when they reported symptoms of acute respiratory illness (ARI) of ≤7 days of duration (cases). Clinical outcomes were assessed at enrollment and two weeks after. Re-enrollment was allowed. Nasal-pharyngeal secretions were evaluated for respiratory pathogens by real-time reverse transcription polymerase chain reaction (PCR). Sera were tested for RSV-specific antibody responses by Western Blot, microneutralization assay, and palivizumab competitive antibody assay. RESULTS: During the 2015–2016 respiratory virus season, 7 of 65 (11%) pregnant women with ARI at their initial enrollment and 8 of 77 (10%) pregnant women with ARI during the study period (initial or re-enrollment) had PCR-confirmed RSV infection. Four (50%) PCR-confirmed RSV ARI cases reported symptoms of a lower respiratory tract illness (LRTI), one was hospitalized. Combining PCR and serology data, the RSV attack rate at initial enrollment was 12% (8 of 65), and 13% (10 of 77) based on ARI episodes. Among healthy controls, 28 of 88 (32%) had a Western Blot profile suggestive of a recent RSV infection either in the prior and/or current season. CONCLUSION: RSV had an attack rate of 10–13% among ambulatory pregnant women receiving routine prenatal care during the respiratory virus season. The serology results of healthy controls suggest a potentially higher attack rate. Future studies should be aware of the combined diagnostic strength of PCR and serology to identify RSV infection. As maternal RSV vaccine candidates are evaluated to protect young infants, additional priority should be placed on outcomes of pregnant women. Elsevier Ltd. 2019-06-06 2019-05-10 /pmc/articles/PMC7126758/ /pubmed/31085002 http://dx.doi.org/10.1016/j.vaccine.2019.04.098 Text en © 2019 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hause, Anne M.
Avadhanula, Vasanthi
Maccato, Maurizio L.
Pinell, Phillip M.
Bond, Nanette
Santarcangelo, Patricia
Ferlic-Stark, Laura
Ye, Xunyan
Iwuchukwu, Obinna
Maurer, Lauren
Aideyan, Letisha
Dao, Kelly
McBride, Trevor
Piedra, Pedro A.
Munoz, Flor M.
Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women
title Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women
title_full Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women
title_fullStr Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women
title_full_unstemmed Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women
title_short Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women
title_sort clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126758/
https://www.ncbi.nlm.nih.gov/pubmed/31085002
http://dx.doi.org/10.1016/j.vaccine.2019.04.098
work_keys_str_mv AT hauseannem clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT avadhanulavasanthi clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT maccatomauriziol clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT pinellphillipm clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT bondnanette clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT santarcangelopatricia clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT ferlicstarklaura clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT yexunyan clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT iwuchukwuobinna clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT maurerlauren clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT aideyanletisha clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT daokelly clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT mcbridetrevor clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT piedrapedroa clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen
AT munozflorm clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen